Maxim Group Reiterates “$5.00” Price Target for Soligenix (SNGX)

Maxim Group set a $5.00 price objective on Soligenix (NASDAQ:SNGX) in a report released on Wednesday. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reaffirmed a buy rating and issued a $11.00 price objective on shares of Soligenix in a research report on Thursday, September 21st.

Soligenix (NASDAQ SNGX) opened at $2.27 on Wednesday. Soligenix has a 12-month low of $1.74 and a 12-month high of $5.08.

Soligenix (NASDAQ:SNGX) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.15. The business had revenue of $1.82 million for the quarter, compared to analysts’ expectations of $1.36 million. Soligenix had a negative return on equity of 112.81% and a negative net margin of 90.93%. analysts expect that Soligenix will post -1.28 EPS for the current fiscal year.

In other Soligenix news, insider Spa Essetifin acquired 293,510 shares of the stock in a transaction that occurred on Wednesday, November 29th. The shares were acquired at an average cost of $2.12 per share, with a total value of $622,241.20. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.03% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This article was first reported by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this article on another site, it was illegally stolen and reposted in violation of U.S. and international copyright legislation. The original version of this article can be viewed at https://stocknewstimes.com/2018/01/06/maxim-group-reiterates-5-00-price-target-for-soligenix-sngx.html.

About Soligenix

Soligenix, Inc is a late-stage biopharmaceutical company. The Company is focused on developing and commercializing products to treat rare diseases. The Company operates through two segments: BioTherapeutics and Vaccines/BioDefense. Its BioTherapeutics segment is developing a photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma (CTCL), formulations of oral beclomethasone 17,21-dipropionate (BDP) for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, and its innate defense regulator (IDR) technology, dusquetide (SGX942) for the treatment of oral mucositis in head and neck cancer.

Receive News & Ratings for Soligenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soligenix and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply